Emily N. Gould
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Emily N. Gould has a total of 62 co-authors. Here are the top co-authors by number of shared publications:
- Mary Katherine Tolbert
Gastrointestinal Laboratory, Department of Small Animal Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Texas A&M University, College Station, TX
9 shared publications - Joerg Manfred Steiner
Gastrointestinal Laboratory, Texas A&M University, College Station, TX
3 shared publications J.M. Steiner
Gastrointestinal Laboratory Texas A&M University College Station TX
2 shared publications- Joshua M. Price
Research Computing Support, Office of Innovative Technologies, University of Tennessee, Knoxville, Tennessee
2 shared publications - Kathleen Moira Aicher
Gastrointestinal Laboratory, Department of Small Animal Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Texas A&M University, College Station, TX
2 shared publications Song Zhang
Peter O’Donnell Jr. School of Public Health, Southwestern Medical Center, University of Texas, Dallas, TX
2 shared publications
Latest Publications
- Open Access
- 23 October 2026
- Published by American Veterinary Medical Association (AVMA) in Journal of the American Veterinary Medical Association
- p. 1-9
Diagnosis of exocrine pancreatic insufficiency in dogs requires use of a newly adjusted reference range and diagnostic cutoff for measurement of trypsin-like immunoreactivity
Objective: To adjust the reference interval (RI) for a commercially available canine trypsin-like immunoreactivity (cTLI) assay and the cutoff value for the diagnosis of exocrine pancreatic insufficiency (EPI). Methods: Lower limit of the RI was calculated based on the fifth percentile of cTLI concentrations in 102 clinically healthy dogs. Questionnaires were sent to clinicians for cases with serum cTLI concentrations ≤ 10 µg/L. Five board-certified small animal internists blinded to serum cTLI concentration individually reviewed questionnaire responses to clinically classify each dog. Dogs were classified as “EPI” or “not EPI” based on the consensus when ≥ 4 internists assigned the same classification. The cutoff was determined by maximizing the weighted Youden index (1.34 × sensitivity + 0.67 × specificity – 1). Sensitivity was prioritized, as false negatives were considered more deleterious than false positives. Results: The calculated lower RI limit was ≥ 11.8 µg/L. Forty-seven dogs each were classified as EPI and not EPI. The median (range) serum cTLI concentrations were 1.5 µg/L (0.9 to 7.2) for the EPI dogs and 8.3 µg/L (2.2 to 10.0) for the not EPI dogs. The optimal diagnostic cutoff was 5.5 µg/L, with a sensitivity of 95.7% and specificity of 83.0%. Conclusions: Use of the updated RI (≥ 11.8 µg/L) and diagnostic cutoff value for EPI (5.5 µg/L) should reduce false-negative results when using this commercial assay. Clinical Relevance: There has been an upward shift in serum cTLI measurements with this commercial assay, consistent with clinical observations.
- 23 October 2026
- Published by American Veterinary Medical Association (AVMA) in Journal of the American Veterinary Medical Association
- p. 1-9
Open AccessDiagnosis of exocrine pancreatic insufficiency in dogs requires use of a newly adjusted reference range and diagnostic cutoff for measurement of trypsin-like immunoreactivity
Objective: To adjust the reference interval (RI) for a commercially available canine trypsin-like immunoreactivity (cTLI) assay and the cutoff value for the diagnosis of exocrine pancreatic insufficiency (EPI). Methods: Lower limit of the RI was calculated based on the fifth percentile of cTLI concentrations in 102 clinically healthy dogs. Questionnaires were sent to clinicians for cases with serum cTLI concentrations ≤ 10 µg/L. Five board-certified small animal internists blinded to serum cTLI concentration individually reviewed questionnaire responses to clinically classify each dog. Dogs were classified as “EPI” or “not EPI” based on the consensus when ≥ 4 internists assigned the same classification. The cutoff was determined by maximizing the weighted Youden index (1.34 × sensitivity + 0.67 × specificity – 1). Sensitivity was prioritized, as false negatives were considered more deleterious than false positives. Results: The calculated lower RI limit was ≥ 11.8 µg/L. Forty-seven dogs each were classified as EPI and not EPI. The median (range) serum cTLI concentrations were 1.5 µg/L (0.9 to 7.2) for the EPI dogs and 8.3 µg/L (2.2 to 10.0) for the not EPI dogs. The optimal diagnostic cutoff was 5.5 µg/L, with a sensitivity of 95.7% and specificity of 83.0%. Conclusions: Use of the updated RI (≥ 11.8 µg/L) and diagnostic cutoff value for EPI (5.5 µg/L) should reduce false-negative results when using this commercial assay. Clinical Relevance: There has been an upward shift in serum cTLI measurements with this commercial assay, consistent with clinical observations.
- Open Access
- 1 June 2026
- Published by American Veterinary Medical Association (AVMA) in American Journal of Veterinary Research
- Vol. 87 (6)
Histoplasma antigen test results are influenced by the urine collection method in dogs
Objective: A commercially available Histoplasma urine antigen enzyme immunoassay (MV antigen EIA; MiraVista Diagnostics) is widely used to support the diagnosis of histoplasmosis in dogs; however, a standardized urine collection technique does not exist. The objective was to evaluate agreement between 3 urine collection techniques (free catch [FC], cystocentesis [cysto], and iatrogenically hospital-contaminated cystocentesis [contam]) using the MV antigen EIA in dogs and to determine associated false-positive rates (FPRs). Methods: Participants were 30 dogs suspected of histoplasmosis and 30 temporally matched, healthy controls. In this 12-month prospective study (December 2023 to 2024), 3 urine samples (FC, cysto, and contam) were collected within 24 hours from each dog. Agreement between methods was assessed using the McNemar test and Cohen κ coefficients. False-positive rates were calculated using clinical diagnosis as the reference standard. Results: 3 clinically ill dogs were definitively diagnosed with histoplasmosis. Agreement was substantial between cysto and contam samples (κ = 0.68; 95% CI, 0.39 to 0.97) and moderate between cysto and FC (κ = 0.45; 95% CI, 0.07 to 0.82) and FC and contam samples (κ = 0.42; 95% CI, 0.10 to 0.75). The overall FPR was 16% (9 of 57; 95% CI, 6 to 25%). The cysto samples had the lowest FPR (4% [2 of 57]; 95% CI, 1 to 12%), followed by FC (7% [4 of 57]; 95% CI, 3 to 17%) and contam (11% [6 of 57]; 95% CI, 5 to 21%). Conclusions: While all collection techniques demonstrated reasonable agreement, FC and contam samples were more prone to false positives. Clinical Relevance: Clinicians should confirm contam low-level positive results with sterile cysto to improve diagnostic accuracy and clinical decision-making for histoplasmosis in dogs.
- 1 June 2026
- Published by American Veterinary Medical Association (AVMA) in American Journal of Veterinary Research
- Vol. 87 (6)
Open AccessHistoplasma antigen test results are influenced by the urine collection method in dogs
Objective: A commercially available Histoplasma urine antigen enzyme immunoassay (MV antigen EIA; MiraVista Diagnostics) is widely used to support the diagnosis of histoplasmosis in dogs; however, a standardized urine collection technique does not exist. The objective was to evaluate agreement between 3 urine collection techniques (free catch [FC], cystocentesis [cysto], and iatrogenically hospital-contaminated cystocentesis [contam]) using the MV antigen EIA in dogs and to determine associated false-positive rates (FPRs). Methods: Participants were 30 dogs suspected of histoplasmosis and 30 temporally matched, healthy controls. In this 12-month prospective study (December 2023 to 2024), 3 urine samples (FC, cysto, and contam) were collected within 24 hours from each dog. Agreement between methods was assessed using the McNemar test and Cohen κ coefficients. False-positive rates were calculated using clinical diagnosis as the reference standard. Results: 3 clinically ill dogs were definitively diagnosed with histoplasmosis. Agreement was substantial between cysto and contam samples (κ = 0.68; 95% CI, 0.39 to 0.97) and moderate between cysto and FC (κ = 0.45; 95% CI, 0.07 to 0.82) and FC and contam samples (κ = 0.42; 95% CI, 0.10 to 0.75). The overall FPR was 16% (9 of 57; 95% CI, 6 to 25%). The cysto samples had the lowest FPR (4% [2 of 57]; 95% CI, 1 to 12%), followed by FC (7% [4 of 57]; 95% CI, 3 to 17%) and contam (11% [6 of 57]; 95% CI, 5 to 21%). Conclusions: While all collection techniques demonstrated reasonable agreement, FC and contam samples were more prone to false positives. Clinical Relevance: Clinicians should confirm contam low-level positive results with sterile cysto to improve diagnostic accuracy and clinical decision-making for histoplasmosis in dogs.
- Open Access
- 16 April 2026
- Published by SAGE Publications in Journal of Feline Medicine and Surgery
- Vol. 28 (5)
Gastrointestinal microbiota and fecal fatty acids of cats with exocrine pancreatic insufficiency
Objectives: The aim of the present study was to identify differences in fecal analytes (ie, microbiota, fatty acids [FAs]) in cats with exocrine pancreatic insufficiency (EPI) compared with healthy controls, and describe clinical signs at baseline and short-term follow-up. Methods: A cross-sectional, observational study was conducted of 55 client-owned cats with EPI and 37 healthy client-owned blood donor control cats. Eligible cases had a feline trypsin-like immunoreactivity (fTLI) consistent with EPI. Fecal samples were analyzed for fecal microbiota dysbiosis index (DI) and FAs. Serum and fecal analytes from controls were compared with EPI cats using parametric and non-parametric methods including general linear models to adjust for potential confounding by signalment differences. Clinical signs were described for cats with EPI at enrollment and for one short-term follow-up time point. Results: Fecal DI and FAs were abnormal in EPI cases compared with controls. Cats with EPI had a higher median DI (1.5 [range −2.6 to 3.8]), total FAs (74.1 µg/g [range 4.7–162]), arachidonic acid (2.54 µg/g [range 0.03–17.0]) and nervonic acid (0.37 µg/g [range 0.02–1.5]) than controls (–3 [range −4.4 to −0.6], 19.7 µg/g [range 9.4–75.2], 0.57 µg/g [range 0.32–1.51] and 0.17 µg/g [range 0.09–0.54], respectively), and a lower median Peptacetobacter hiranonis (4.8 log DNA [range 0.1–6.1]) compared with controls (5.9 log DNA [range 3.2–6.8]). The most common clinical signs were weight loss and appetite disturbances. Conclusions and relevance: Cats with EPI have alterations in fecal microbiota and FA, and clinical signs in this population of cats were similar to those previously reported.
- 16 April 2026
- Published by SAGE Publications in Journal of Feline Medicine and Surgery
- Vol. 28 (5)
Open AccessGastrointestinal microbiota and fecal fatty acids of cats with exocrine pancreatic insufficiency
Objectives: The aim of the present study was to identify differences in fecal analytes (ie, microbiota, fatty acids [FAs]) in cats with exocrine pancreatic insufficiency (EPI) compared with healthy controls, and describe clinical signs at baseline and short-term follow-up. Methods: A cross-sectional, observational study was conducted of 55 client-owned cats with EPI and 37 healthy client-owned blood donor control cats. Eligible cases had a feline trypsin-like immunoreactivity (fTLI) consistent with EPI. Fecal samples were analyzed for fecal microbiota dysbiosis index (DI) and FAs. Serum and fecal analytes from controls were compared with EPI cats using parametric and non-parametric methods including general linear models to adjust for potential confounding by signalment differences. Clinical signs were described for cats with EPI at enrollment and for one short-term follow-up time point. Results: Fecal DI and FAs were abnormal in EPI cases compared with controls. Cats with EPI had a higher median DI (1.5 [range −2.6 to 3.8]), total FAs (74.1 µg/g [range 4.7–162]), arachidonic acid (2.54 µg/g [range 0.03–17.0]) and nervonic acid (0.37 µg/g [range 0.02–1.5]) than controls (–3 [range −4.4 to −0.6], 19.7 µg/g [range 9.4–75.2], 0.57 µg/g [range 0.32–1.51] and 0.17 µg/g [range 0.09–0.54], respectively), and a lower median Peptacetobacter hiranonis (4.8 log DNA [range 0.1–6.1]) compared with controls (5.9 log DNA [range 3.2–6.8]). The most common clinical signs were weight loss and appetite disturbances. Conclusions and relevance: Cats with EPI have alterations in fecal microbiota and FA, and clinical signs in this population of cats were similar to those previously reported.
- 1 December 2024
- Published by American Veterinary Medical Association (AVMA) in Journal of the American Veterinary Medical Association
- Vol. 262 (12) , 1-9
Cross-sectional survey of 43,517 dogs in the Dog Aging Project identifies owner-reported lifetime prevalence and characteristics of gastrointestinal disease
OBJECTIVE: To evaluate the prevalence of and characteristics associated with owner-reported gastrointestinal (GI) disease in companion dogs within the US. METHODS: Cross-sectional owner-reported survey study of 43,517 dogs enrolled in the DAP between December 26, 2019, and December 31, 2022. Dogs were grouped on the basis of having an owner-reported GI disorder (ORGID) versus not having that ORGID at any point in their history (control group). Multivariable logistic regression analysis was used to estimate the association between dog characteristics and ORGIDs with prevalence ORs (PORs). RESULTS: Of the 43,517 dogs in the DAP Pack, 30,677 (70%) had no history of ORGIDs and 12,840 (30%) had at least 1 ORGID. The most common ORGIDs included infectious diseases (7,580 of 43,517 [17%]), chronic diarrhea (1,316 [3%]), foreign bodies (1,086 [2%]), anal sac impactions (1,031 [2%]), pancreatitis (857 [2%]), inflammatory GI disease (615 [1%]), chronic vomiting (519 [1%]), and acute hemorrhagic diarrhea syndrome (388 [1%]). Compared to controls, dogs with noninfectious ORGIDs had greater odds of having a history of being castrated (POR, 2.55; 95% CI, 2.29 to 2.85), underweight (POR, 1.58; 95% CI, 1.47 to 1.70), or fed primarily canned food (POR, 2.51; 95% CI, 2.21 to 2.85) or receiving probiotics (POR, 1.69; 95% CI, 1.58 to 1.81) or nonprescription GI medications (POR, 4.06; 95% CI, 3.80 to 4.33). CONCLUSIONS: Dog owners in the US recruited from the general public reported a high prevalence of GI disorders in their dogs. Infectious and noninfectious ORGIDs were reported with approximately equal frequency. CLINICAL RELEVANCE: Dogs with ORGIDs were more likely to have a history of receiving probiotics or nonprescription GI medications, which may indicate that owners are changing lifestyle practices to accommodate these GI disorders, although future longitudinal research is needed.
- 1 December 2024
- Published by American Veterinary Medical Association (AVMA) in Journal of the American Veterinary Medical Association
- Vol. 262 (12) , 1-9
Cross-sectional survey of 43,517 dogs in the Dog Aging Project identifies owner-reported lifetime prevalence and characteristics of gastrointestinal disease
OBJECTIVE: To evaluate the prevalence of and characteristics associated with owner-reported gastrointestinal (GI) disease in companion dogs within the US. METHODS: Cross-sectional owner-reported survey study of 43,517 dogs enrolled in the DAP between December 26, 2019, and December 31, 2022. Dogs were grouped on the basis of having an owner-reported GI disorder (ORGID) versus not having that ORGID at any point in their history (control group). Multivariable logistic regression analysis was used to estimate the association between dog characteristics and ORGIDs with prevalence ORs (PORs). RESULTS: Of the 43,517 dogs in the DAP Pack, 30,677 (70%) had no history of ORGIDs and 12,840 (30%) had at least 1 ORGID. The most common ORGIDs included infectious diseases (7,580 of 43,517 [17%]), chronic diarrhea (1,316 [3%]), foreign bodies (1,086 [2%]), anal sac impactions (1,031 [2%]), pancreatitis (857 [2%]), inflammatory GI disease (615 [1%]), chronic vomiting (519 [1%]), and acute hemorrhagic diarrhea syndrome (388 [1%]). Compared to controls, dogs with noninfectious ORGIDs had greater odds of having a history of being castrated (POR, 2.55; 95% CI, 2.29 to 2.85), underweight (POR, 1.58; 95% CI, 1.47 to 1.70), or fed primarily canned food (POR, 2.51; 95% CI, 2.21 to 2.85) or receiving probiotics (POR, 1.69; 95% CI, 1.58 to 1.81) or nonprescription GI medications (POR, 4.06; 95% CI, 3.80 to 4.33). CONCLUSIONS: Dog owners in the US recruited from the general public reported a high prevalence of GI disorders in their dogs. Infectious and noninfectious ORGIDs were reported with approximately equal frequency. CLINICAL RELEVANCE: Dogs with ORGIDs were more likely to have a history of receiving probiotics or nonprescription GI medications, which may indicate that owners are changing lifestyle practices to accommodate these GI disorders, although future longitudinal research is needed.
- Open Access
- 1 November 2024
- Published by Oxford University Press (OUP) in Journal of Veterinary Internal Medicine
- Vol. 38 (6) , 3235-3241
Pharmacodynamics of 2 dosages of orally administered esomeprazole in client-owned, healthy dogs: A prospective, crossover study
Background: Esomeprazole use is increasing in dogs, but the gastrointestinal adverse events associated with q12h dosing necessitate pharmacodynamic evaluation of a reduced dose and frequency of administration. Objectives: To compare the efficacy of 2 doses of (q24h) esomeprazole in raising intragastric pH in dogs. Animals: Nine healthy, client-owned dogs, >20 kg. Methods: Prospective, randomized, double blinded, crossover study. Esomeprazole (0.5 or 1 mg/kg q24h) was orally administered for up to 5 days per treatment arm, and the mean percentage time intragastric pH was ≥3 (MPT3) and ≥4 (MPT4) for 24 hours periods were compared to pretreatment pH using a continuous pH monitoring system. Dogs failing to reach pH goals (MPT3 ≥75%, MPT4 ≥66%) with once daily dosing received esomeprazole 1 mg/kg PO q12h to determine if a higher dose would improve acid suppression. Results: No significant difference in the MPT3 or MPT4 was identified between treatments for any time point (P > .05). Both doses increased the MPT pH ≥3 and 4 median [range] (0.5 mg/kg, 1 mg/kg) on days 1 (MPT3: 76.8% [44-100], 69.2% [28.2-100]; MPT4: 65.6% [16.7-99.3], 54.9% [14.9-93.3]; P = .0009) and 2 (MPT3:77.2% [27.4-100], 75.4% [49.4-89.5]; MPT4: 66.3% [15.5-100], 59.7% [33.8-81.2]; P = .0005) of PPI treatment compared to pretreatment (MPT3: 58.3% [0.02-93.9], 52.6% [6.1-94.7]; MPT4: 25.2% [0-86.8], 32.4% [1.8-89.3]). Six dogs (66%, [0.36, 0.97]) reached pH goals established in humans with q24h dosing. Conclusions and Clinical Importance: Both q24h PO esomeprazole doses were effective in raising intragastric pH, despite high intersubject variability, but 33% of dogs required q12h dosing to reach pH goals.
- 1 November 2024
- Published by Oxford University Press (OUP) in Journal of Veterinary Internal Medicine
- Vol. 38 (6) , 3235-3241
Open AccessPharmacodynamics of 2 dosages of orally administered esomeprazole in client-owned, healthy dogs: A prospective, crossover study
Background: Esomeprazole use is increasing in dogs, but the gastrointestinal adverse events associated with q12h dosing necessitate pharmacodynamic evaluation of a reduced dose and frequency of administration. Objectives: To compare the efficacy of 2 doses of (q24h) esomeprazole in raising intragastric pH in dogs. Animals: Nine healthy, client-owned dogs, >20 kg. Methods: Prospective, randomized, double blinded, crossover study. Esomeprazole (0.5 or 1 mg/kg q24h) was orally administered for up to 5 days per treatment arm, and the mean percentage time intragastric pH was ≥3 (MPT3) and ≥4 (MPT4) for 24 hours periods were compared to pretreatment pH using a continuous pH monitoring system. Dogs failing to reach pH goals (MPT3 ≥75%, MPT4 ≥66%) with once daily dosing received esomeprazole 1 mg/kg PO q12h to determine if a higher dose would improve acid suppression. Results: No significant difference in the MPT3 or MPT4 was identified between treatments for any time point (P > .05). Both doses increased the MPT pH ≥3 and 4 median [range] (0.5 mg/kg, 1 mg/kg) on days 1 (MPT3: 76.8% [44-100], 69.2% [28.2-100]; MPT4: 65.6% [16.7-99.3], 54.9% [14.9-93.3]; P = .0009) and 2 (MPT3:77.2% [27.4-100], 75.4% [49.4-89.5]; MPT4: 66.3% [15.5-100], 59.7% [33.8-81.2]; P = .0005) of PPI treatment compared to pretreatment (MPT3: 58.3% [0.02-93.9], 52.6% [6.1-94.7]; MPT4: 25.2% [0-86.8], 32.4% [1.8-89.3]). Six dogs (66%, [0.36, 0.97]) reached pH goals established in humans with q24h dosing. Conclusions and Clinical Importance: Both q24h PO esomeprazole doses were effective in raising intragastric pH, despite high intersubject variability, but 33% of dogs required q12h dosing to reach pH goals.
- Open Access
- 1 July 2024
- Published by Oxford University Press (OUP) in Journal of Veterinary Internal Medicine
- Vol. 38 (4) , 2305-2315
Retrospective evaluation of the effect of acid suppressant drugs on leukocyte ratios in dogs with mast cell tumors
Background: Acid suppressant drugs (ASDs) are commonly used to decrease gastric acid production, but some evidence exists that ASDs exert immunomodulatory effects. Such an effect has not been investigated in dogs for which ASDs are routinely prescribed. Hypothesis: Compared to naïve subjects, dogs treated with ASDs will exhibit differences in leukocyte ratios after treatment. Animals: Fifty-one dogs with mast cell tumors (MCTs). Materials and Methods: Dogs with MCT that were either AS naïve or treated with ASDs (i.e., histamine-2-receptor antagonists [H2RA] or proton pump inhibitors [PPI]) were included in this retrospective study. Subjects were categorized into 3 treatment groups (AS naïve, H2RA treated, and PPI treated), and leukocyte ratios (neutrophil:eosinophil, lymphocyte:monocyte, and neutrophil:lymphocyte [NLR]) were calculated before and after treatment. A mixed effects analysis of variance on ranks was used to assess differences in ratios between treatments, between pre- and post-treatment time points, and between pre- and post-time points for each treatment. Concurrent administration of antihistamines, corticosteroids, and chemotherapeutic drugs was assessed as a confounding factor. Results: Famotidine (n = 14/14) and omeprazole (n = 12/12) were the only H2RA and PPI used, respectively. Dogs receiving famotidine had a significant increase in median NLR from pre- to post-treatment (3.429; range, 1.417–15 to 5.631; range, 2.654–92; P < 0.01) compared to PPI treated or AS naïve dogs. No differences existed in chemotherapeutic drug or corticosteroid use between groups. Conclusions: A significant difference in NLR was identified in famotidine treated dogs compared with omeprazole treated or AS naïve dogs.
- 1 July 2024
- Published by Oxford University Press (OUP) in Journal of Veterinary Internal Medicine
- Vol. 38 (4) , 2305-2315
Open AccessRetrospective evaluation of the effect of acid suppressant drugs on leukocyte ratios in dogs with mast cell tumors
Background: Acid suppressant drugs (ASDs) are commonly used to decrease gastric acid production, but some evidence exists that ASDs exert immunomodulatory effects. Such an effect has not been investigated in dogs for which ASDs are routinely prescribed. Hypothesis: Compared to naïve subjects, dogs treated with ASDs will exhibit differences in leukocyte ratios after treatment. Animals: Fifty-one dogs with mast cell tumors (MCTs). Materials and Methods: Dogs with MCT that were either AS naïve or treated with ASDs (i.e., histamine-2-receptor antagonists [H2RA] or proton pump inhibitors [PPI]) were included in this retrospective study. Subjects were categorized into 3 treatment groups (AS naïve, H2RA treated, and PPI treated), and leukocyte ratios (neutrophil:eosinophil, lymphocyte:monocyte, and neutrophil:lymphocyte [NLR]) were calculated before and after treatment. A mixed effects analysis of variance on ranks was used to assess differences in ratios between treatments, between pre- and post-treatment time points, and between pre- and post-time points for each treatment. Concurrent administration of antihistamines, corticosteroids, and chemotherapeutic drugs was assessed as a confounding factor. Results: Famotidine (n = 14/14) and omeprazole (n = 12/12) were the only H2RA and PPI used, respectively. Dogs receiving famotidine had a significant increase in median NLR from pre- to post-treatment (3.429; range, 1.417–15 to 5.631; range, 2.654–92; P < 0.01) compared to PPI treated or AS naïve dogs. No differences existed in chemotherapeutic drug or corticosteroid use between groups. Conclusions: A significant difference in NLR was identified in famotidine treated dogs compared with omeprazole treated or AS naïve dogs.
- 22 December 2022
- Published by Elsevier in Veterinary Immunology and Immunopathology
- Vol. 256, 110539
Esomeprazole induces structural changes and apoptosis and alters function of in vitro canine neoplastic mast cells
- 22 December 2022
- Published by Elsevier in Veterinary Immunology and Immunopathology
- Vol. 256, 110539
Esomeprazole induces structural changes and apoptosis and alters function of in vitro canine neoplastic mast cells
- 1 January 2019
- Published by American Animal Hospital Association in Journal of the American Animal Hospital Association
- Vol. 55 (4) , e554-05
Suspected Iatrogenic Seeding of Oral Melanoma Secondary to Endotracheal Intubation in a Dog
A 10 yr old castrated male pug was presented with a 3 day history of intermittent dyspnea, cough, inappetence, and inability to breathe while sleeping. He had previously received hypofractionated radiation therapy for an amelanotic oral malignant melanoma (OMM) 7 mo prior to presentation. At presentation, the dog was gasping and dyspneic. Oral examination identified the OMM on the right hard palate. Thoracic radiographs revealed an angular soft-tissue opacity within the trachea just distal to the thoracic inlet. No evidence of pulmonary metastatic disease was seen. Tracheoscopy identified a pedunculated, nonpigmented mass within the lumen of the distal trachea near the carina. Treatment options were presented to the owners and included tracheal stenting or tracheal resection and anastomosis. Because of the poor prognosis, the owners elected humane euthanasia. Postmortem examination confirmed the presence of melanoma in the distal trachea; no other sites of OMM metastasis were identified. The cause of OMM development in the distal trachea in this case is suspected to have resulted from mechanical tumor cell seeding during endotracheal tube placement for general anesthesia 7 mo prior to presentation. Despite the reported rarity of mechanical tumor seeding, this potential complication warrants consideration in dogs with OMM.
- 1 January 2019
- Published by American Animal Hospital Association in Journal of the American Animal Hospital Association
- Vol. 55 (4) , e554-05
Suspected Iatrogenic Seeding of Oral Melanoma Secondary to Endotracheal Intubation in a Dog
A 10 yr old castrated male pug was presented with a 3 day history of intermittent dyspnea, cough, inappetence, and inability to breathe while sleeping. He had previously received hypofractionated radiation therapy for an amelanotic oral malignant melanoma (OMM) 7 mo prior to presentation. At presentation, the dog was gasping and dyspneic. Oral examination identified the OMM on the right hard palate. Thoracic radiographs revealed an angular soft-tissue opacity within the trachea just distal to the thoracic inlet. No evidence of pulmonary metastatic disease was seen. Tracheoscopy identified a pedunculated, nonpigmented mass within the lumen of the distal trachea near the carina. Treatment options were presented to the owners and included tracheal stenting or tracheal resection and anastomosis. Because of the poor prognosis, the owners elected humane euthanasia. Postmortem examination confirmed the presence of melanoma in the distal trachea; no other sites of OMM metastasis were identified. The cause of OMM development in the distal trachea in this case is suspected to have resulted from mechanical tumor cell seeding during endotracheal tube placement for general anesthesia 7 mo prior to presentation. Despite the reported rarity of mechanical tumor seeding, this potential complication warrants consideration in dogs with OMM.
- 1 September 2017
- Published by Elsevier in Veterinary Parasitology
- Vol. 244, 144-153
Evaluation of surface antigen TF1.17 in feline Tritrichomonas foetus isolates
- 1 September 2017
- Published by Elsevier in Veterinary Parasitology
- Vol. 244, 144-153
Evaluation of surface antigen TF1.17 in feline Tritrichomonas foetus isolates
- Open Access
- 1 September 2017
- Published by Oxford University Press (OUP) in Journal of Veterinary Internal Medicine
- Vol. 31 (5) , 1414-1419
Evaluation of Gastric pH and Serum Gastrin Concentrations in Cats with Chronic Kidney Disease
Chronic kidney disease (CKD) is a highly prevalent condition in cats. Advanced CKD is associated with hyporexia and vomiting, which typically are attributed to uremic toxins and gastric hyperacidity. However, gastric pH studies have not been performed in cats with CKD. To determine if cats with CKD have decreased gastric pH compared to age-matched, healthy cats. Based on previous work demonstrating an association of hypergastrinemia and CKD, we hypothesized that cats with CKD would have decreased gastric pH compared to healthy, age-matched control cats. 10 CKD cats; 9 healthy control cats. All cats with concurrent disease were excluded on the basis of history, physical examination, CBC, plasma biochemistry profile, urinalysis, urine culture, serum total thyroxine concentration, and serum symmetric dimethylarginine concentration (controls only) obtained within 24 hours of pH monitoring and assessment of serum gastrin concentrations. Serum for gastrin determination was collected, and 12-hour continuous gastric pH monitoring was performed in all cats. Serum gastrin concentration, mean pH, and percentage time that gastric pH was strongly acidic (pH P-value = 0.713) or of any pH parameters including mean ± SD gastric pH (CKD, 1.8 ± 0.5; healthy, 1.6 ± 0.3; P-value = 0.23). These findings suggest that cats with CKD may not have gastric hyperacidity compared to healthy cats and, therefore, may not need acid suppression. Thus, further studies to determine if there is a benefit to acid suppression in cats with CKD are warranted.
- 1 September 2017
- Published by Oxford University Press (OUP) in Journal of Veterinary Internal Medicine
- Vol. 31 (5) , 1414-1419
Open AccessEvaluation of Gastric pH and Serum Gastrin Concentrations in Cats with Chronic Kidney Disease
Chronic kidney disease (CKD) is a highly prevalent condition in cats. Advanced CKD is associated with hyporexia and vomiting, which typically are attributed to uremic toxins and gastric hyperacidity. However, gastric pH studies have not been performed in cats with CKD. To determine if cats with CKD have decreased gastric pH compared to age-matched, healthy cats. Based on previous work demonstrating an association of hypergastrinemia and CKD, we hypothesized that cats with CKD would have decreased gastric pH compared to healthy, age-matched control cats. 10 CKD cats; 9 healthy control cats. All cats with concurrent disease were excluded on the basis of history, physical examination, CBC, plasma biochemistry profile, urinalysis, urine culture, serum total thyroxine concentration, and serum symmetric dimethylarginine concentration (controls only) obtained within 24 hours of pH monitoring and assessment of serum gastrin concentrations. Serum for gastrin determination was collected, and 12-hour continuous gastric pH monitoring was performed in all cats. Serum gastrin concentration, mean pH, and percentage time that gastric pH was strongly acidic (pH P-value = 0.713) or of any pH parameters including mean ± SD gastric pH (CKD, 1.8 ± 0.5; healthy, 1.6 ± 0.3; P-value = 0.23). These findings suggest that cats with CKD may not have gastric hyperacidity compared to healthy cats and, therefore, may not need acid suppression. Thus, further studies to determine if there is a benefit to acid suppression in cats with CKD are warranted.